Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I gotcha.
That's my point why would big pharma be doing it. 2 billion is 2 billion regardless of shares.
If Dan doesn't do an offering it doesn't matter
I highly doubt Its BP. were already in bed with Amgen, merck, astra. Etc.
More likely funds that are short bio and ADXS with nowhere to go plus lack of new buyers
Nothing new. It's exactly what Hans from IR emailed me last week. Waste
Not sure what new is going to be presented. This is from Hans:
Hi John,
The presentation at SGO will be deeper analyses of the already-completed GOG study.
Best,
Hans
Hans Vitzthum
Managing Director
LifeSci Advisors, LLC.
250 West 55th Street - Suite 16B
New York, NY 10019
Date: Thursday, March 2, 2017 at 8:57 AM
To: Hans Vitzthum <hans@lifesciadvisors.com>
Subject: 3/14 presentation
Report TOS
IG is correct it's oct. just google advaxis warrants expiration and it brings you to the website press release
Need a deal. upfront cash. Never has these pres. Jump started share price as long as I've been here.
Like 200 mill upfront
Catt. Can u elaborate what u saw in 10q. Thanks in advance.
I meant NEW
Wouldn't ADXS need to disclose pre market any need info being presented?
Hope so.
Not sure what new is going to be presented. This is from Hans:
Hi John,
The presentation at SGO will be deeper analyses of the already-completed GOG study.
Best,
Hans
Hans Vitzthum
Managing Director
LifeSci Advisors, LLC.
250 West 55th Street - Suite 16B
New York, NY 10019
Date: Thursday, March 2, 2017 at 8:57 AM
To: Hans Vitzthum <hans@lifesciadvisors.com>
Subject: 3/14 presentation
IG. I agree they can't be making any money holding in the 9 range after they pay interest. We've been here awhile now. It has to be for some other reason - most likely deal making.
I think James said "this is all planned" with regards to the news coming out. I hope next week before the conference they drop Axal partnership...
I'm with you Trader. I've watching it bang its head against 9.41 all day.. Hoping for a strong close
That's exactly my point you're saying Sellas is only paying for the combo with Sellas implying ADXS is on the hook for all other trials which isn't the case. Axal cervical is the first hit that has the potential to cross home plate hence my comment
M,
Correct but the lead candidate is Axal cervical and that too is paid for the phase 3 trials
We need to break through that 9.40 wall. Come on
Pretty much. The money for the warrants go to ADXS as opposed to the option writer.
I do. I'm all warrants. Like an option the conversion price is 5 bucks. Good until 10/18. Hard to trade so it's a buy and hold strategy
Great point Dawson - regarding the continual hiring of executive type positions.
Easy, just curious why would market makers care if this gravitates upward?
WORD ! Fbg just dropped the mic. Lol. Excellent post and I agree
I don't think it mattes much how we vote - it depends on fund families and it doesn't look good for the little guy....This blows\
The author is a Reuters contributor. The opinions expressed are her own.
By Marla Brill
Nov 1 The Occupy Wall Street movement has shown us that many people want their opinions to be heard on how companies conduct business. But if you own a mutual fund, chances are your fund manager is siding with corporations.
Voting with proxies on behalf of shareholders, mutual funds weigh in on a variety of issues such as how companies pay top executives, handle environmental practices, and elect board members. With over one-quarter of the country's stock market value under their control, they wield enormous power over corporate policies.
But Jackie Cook, founder of a website that tracks proxy voting patterns of mutual funds in the U.S. and Canada, says money managers could do a better job of representing shareholder interests. Since 2004, Cook has been tracking the arcane -- yet increasingly important -- issue of how mutual funds cast votes. "Most of the time, they side with management," says the 41-year-old economist and research analyst. "They typically don't lead the way on voting issues."
That certainly holds true for the issue of executive pay, according to the most recent study of mutual fund proxy voting patterns from the American Federation of State, County, and Municipal Employees (AFSME), which used fundvotes.com data. It found that for votes cast from July 2009 through June 2010, the 26 largest mutual funds in the U.S. supported an average of 80 percent of the executive pay proposals initiated by management.
Most those proposals involved equity-based compensation plans aimed at raising pay, says the AFSME report. But the funds supported less than half of proposals initiated by shareholders to increase investor input on how much top managers pull in.
Agreed this news is irrelevant.
She is Fidelity!!
Has to be done 45 days after quarter ends.
Personally I don't think that's enough for a phase 3 asset such as AXAL and what it has shown already. Take away the stock it's a 100 million. NEO received 40 less stock purchase and that has yet to get going. Unless it's only for EU.
Well then if there is a deal soon it would appear equity would be apart of it - which I think blows. I would love a non-dilutive partnership so it can give the stock a chance to run.
Question - how is it beneficial for DOC always to do a purchase with the new partner? I would rather have a non-dilutive deal. I seen a lot of deals with other companies being non-dilutive. Am I missing something on how this benefits / creates shareholder value...
True but I'm a little shocked they burned through almost 4 million options in 2 years via awards. This maybe normal but it seems high to me.
Thnx very much !!!
Xena, curious what app you use for your charts? I like
Check out Brad Loncar's tweet regarding AZN. I can't copy and paste for some reason. Paraphrasing but AZN 2017 is a pivotal year for their immunology portfolio. " We anticipate defining data, in particular from our outstanding Imunno-oncology pipeline and targeted treatments." Bodes well
He's referring to "animal house" it's a joke. Fyi
Ok. I saw that. you must mean 2 mill from the high in Nov. Got it
Warrants expire 10/18. Also, there not as liquid from a trading aspect. I have all warrants and in no rush to sell
Subtract 5 bucks from buyout price.
Really. So quiet.